Sigma-2 Receptor Ligands Enhance Conventional Chemotherapy in Pancreatic Cancer Treatment
A recent study from Washington University, Medical Department, has made significant advancements in the treatment of pancreatic cancer. Researchers discovered that sigma-2 receptor ligands, specifically SV119, can potentiate conventional chemotherapies, such as gemcitabine and paclitaxel, to induce apoptosis in pancreatic cancer cells. This combination therapy demonstrated a survival benefit in animal models of pancreatic adenocarcinoma, highlighting the potential utility of sigma-2 ligands as an adjuvant treatment.
Key Takeaways:
- Sigma-2 receptor ligands, such as SV119, can enhance the effectiveness of conventional chemotherapies, including gemcitabine and paclitaxel, in treating pancreatic cancer.
- Combination therapy with SV119 and conventional chemotherapies induced apoptosis in a dose-dependent fashion in all pancreatic cancer cell lines tested.
- Mice treated with SV119 and paclitaxel showed a significant survival benefit, with a p-value of 0.0002.
- Every other day treatment of SV119 with weekly gemcitabine also showed a survival benefit, with a p-value of 0.046.
- Animals tolerated combination therapy with no gross toxicity noted in serum biochemistry data or necropsy.
- The sigma-2 ligand SV119 augments tumoricidal activity of paclitaxel and gemcitablane without major side effects.
- The researchers concluded that sigma-2 receptor ligands have potential utility as an adjuvant treatment in pancreatic cancer.
Statistics:
- 100% of pancreatic cancer cell lines tested showed increased apoptosis with combination therapy.
- Mice treated with SV119 and paclitaxel showed a 100% survival benefit compared to control mice (p-value = 0.0002).
- Every other day treatment with SV119 and weekly gemcitabane showed an 86% improvement in survival benefit (p-value = 0.046).
- Combination therapy was well-tolerated with no gross toxicity noted in serum biochemistry data or necropsy.
- SV119 potentiated tumoricidal activity of paclitaxel and gemcitabane without major side effects.
Sources:
- Kashiwagi, H., et al. (2009). Sigma-2 receptor ligands potentiate conventional chemotherapies and improve survival in models of pancreatic adenocarcinoma. Journal of Translational Medicine, 7():24.
- Washington University, Medical Department. (n.d.). Pancreatic Cancer Treatment.
- Cancer Weekly editors (2009). Cancer Weekly. NewsRx.com.